Efficacy of combined bland embolization and chemoembolization for huge (≥10 cm) hepatocellular carcinoma.

• 資料種別: 博士論文
• タイトル: Efficacy of combined bland embolization and chemoembolization for huge (≥10 cm) hepatocellular carcinoma.
• 著者・編者: Hidaka, Teruyuki; Anai, Hiroshi; Sakaguchi, Hiroshi; Sueyoshi, Satoru; Tanaka, Toshihiro; Yamamoto, Kiyosei; Morimoto, Kengo; Nishiofuku, Hideyuki; Maeda, Shinsaku; Nagata, Takeshi; Kichikawa, Kimihiko
• 著者標目: Hidaka, Teruyuki; Anai, Hiroshi; Sakaguchi, Hiroshi; Sueyoshi, Satoru; Tanaka, Toshihiro; Yamamoto, Kiyosei; Morimoto, Kengo; Nishiofuku, Hideyuki; Maeda, Shinsaku; Nagata, Takeshi; Kichikawa, Kimihiko
• 出版事項: Taylor & Francis
• 出版年月日等: 2020-02-07
• 出版年（W3CDTF）: 2020-02-07
• 並列タイトル等: 10cm以上の巨大肝細胞癌に対する、ゼラチンスポンジによる肝動脈塞栓術 (bland TAE) と、Lipiodolと抗癌剤による肝動脈化学塞栓術 (TACE) の併用法の治療効果
• タイトル（掲載誌）: Minimally invasive therapy and allied technologies.
• 巻号年月日等（掲載誌）: 30 4
• 掲載巻: 30
• 掲載号: 4
• 掲載ページ: 221-228
• ISSN（掲載誌）: ISSN : 1364-5706
• 授与機関名: 奈良県立医科大学
• 授与年月日: 2020-06-30
• 報告番号: 乙第1462号
• 学位: 博士（医学）
• 本文の言語コード: eng
• 件名標目: huge hepatocellular carcinoma; transarterial chemoembolization; bland embolization
• 対象利用者: 一般
• 一般注記: type:Thesis; Introduction: To assess the efficacy of combined therapy involving bland transarterial embolization using gelatin sponge particles (bland GS-TAE) followed by transarterial chemoembolization using lipiodol mixed with anticancer agents and GS particles (Lip-TACE) to reduce the adverse events and increase the therapeutic effect of Lip-TACE in the treatment of huge (≥10 cm) hepatocellular carcinoma (HCC).Material and methods: Twenty-one consecutive patients with huge HCCs (≥10 cm in diameter) were enrolled in this study. First, bland GS-TAE was performed to reduce the tumor volume, and then Lip-TACE was performed to control the remaining tumor at intervals of around three weeks. Tumor response, survival, and adverse events of this combined therapy were assessed.Results: The tumor response was assessed three months after combined TACE, with complete response in 38.1% and partial response in 57.1% of cases. Severe adverse events were seen in two patients, acute cholecystitis and tumor rupture. The median survival time was 2.7 years, and the one-, two-, three-, and five-year overall survival rates were 76.2%, 66.7%, 42.9%, and 25.0%, respectively.Conclusion: Combined therapy involving bland GS-TAE followed by Lip-TACE can be performed safety and may improve survival in patients with huge HCCs.; 博士（医学）・乙第1462号・令和2年6月30日; © 2020 Society of Medical Innovation and Technology; This is a post-peer-review, pre-copyedit version of an article published in Minimally invasive therapy and allied technologies. The final authenticated version is available online at: https://doi.org/10.1080/13645706.2020.1725580.; identifier:Minimally invasive therapy and allied technologies Vol.30 No.4 p.221-228 (2021 Aug); identifier:13645706; identifier:http://ginmu.naramed-u.ac.jp/dspace/handle/10564/3763; identifier:Minimally invasive therapy and allied technologies., 30(4): 221-228
• 一次資料へのリンクURL: fulltext; http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3763/1/01%e4%b9%991462%e6%9c%ac%e6%96%87%e3%81%ae%e8%a6%81%e6%97%a8.pdf; http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3763/2/02%e4%b9%991462%e5%af%a9%e6%9f%bb%e8%a6%81%e6%97%a8.pdf; http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3763/6/03%e4%b9%991462%e6%9c%ac%e6%96%87.pdf; http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3763/7/04%e4%b9%991462Figure.pdf; http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3763/8/05%e4%b9%991462Table.pdf
• オンライン閲覧公開範囲: インターネット公開
• 関連情報（DOI）: 10.1080/13645706.2020.1725580
• 掲載誌（NCID）: AA11081338; https://ci.nii.ac.jp/ncid/AA11081338
• 連携機関・データベース: 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• 提供元機関・データベース: 奈良県立医科大学 : 奈良県立医科大学機関リポジトリ GINMU